Clinical Trial Update: Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

View source ↗

Summary

Clinical trial update on piperacillin-tazobactam for various bacterial infections in hematology/oncology units has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Infections
• Gram-positive Bacterial Infections
• Klebsiella Infections

Drugs mentioned

• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Gram-Positive Bacterial Infections, Escherichia Coli Infections | Status: COMPLETED